Abstract:Objective To investigate the clinical effect of Tiotropium Bromide combined with Budesonide atomization inhalation in the treatment of chronic obstructive pulmonary disease.Methods A total of 96patients with chronic obstructive pulmonary disease who were treated in outpatient clinic of our hospital from October 2018 to October 2019 were selected as subjects.They were divided into observation group and control group based on double-blind method,48 cases in each group.All patients received basic treatment,the control group was treated with Tiotropium Bromide,and the observation group was combined with Budesonide atomization inhalation therapy based on the control group.The clinical efficacy and adverse reactions of the two groups were compared and analyzed.The changes of lung function,oxygenation index and blood gas index before and after treatment in the two groupswere studied.Results The total effective rate in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After 2weeks of treatment,the levels of forced expiratory volume(FVC),forced expiratory volume in the first second (FEV1),ratio of FEV1 to FVC (FEV1/FVC),oxygenation index,and arterial partial oxygen pressure(PaO2)in the observation group were higher than those in the control group,and partial pressure of carbon dioxide in artery (PaCO2)level was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Tiotropium Bromide combined with Budesonide atomization inhalatio can achieve good clinical efficacy in treating chronic obstructive pulmonary disease,which can significantly improve the hypoxic state and lung function of patients,and has high safety.
杜月君. 噻托溴铵联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的临床效果[J]. 中国当代医药, 2020, 27(17): 65-68.
DU Yue-jun. Clinical effect of Tiotropium Brom ide combined with Budesonide atom ization inhalation in the treatment of chronic obstructive pulmonary disease. 中国当代医药, 2020, 27(17): 65-68.